Clinical and histopathologic predictors of recurrent glomerulonephritis after kidney transplantation

Author:

Chukwu Chukwuma A.12ORCID,Holmberg Christopher3,Storrar Joshua12,Middleton Rachel12,Sinha Smeeta12,Kalra Phillip A.12,Shawki Howida3,Rao Anirudh3

Affiliation:

1. Department of Nephrology Salford Royal hospital Northern Care Alliance NHS foundation trust Salford, Manchester UK

2. Faculty of Biology Medicine and Health Division of cardiovascular medicine The University of Manchester, Oxford Road Manchester UK

3. Department of Nephrology Liverpool university hospitals NHS Foundation Trust Liverpool Merseyside UK

Abstract

AbstractIntroductionWe evaluated the long‐term outcomes of recurrent glomerulonephritis (RGN) using clinical, histopathological, and demographic predictors.MethodsA retrospective cohort study of kidney transplant recipients (KTR) in two renal centers between 2005 and 2020. Clinical and native kidney histological data were analyzed. The risk factors and outcomes of each primary glomerulonephritis subtype were assessed using Cox methods.Result336 recipients with primary glomerulonephritis were analyzed. RGN was diagnosed in 17%, 20%, 25%, and 13% of recipients with IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN) and membranoproliferative glomerulonephritis (MPGN), respectively. Median time to recurrence was shortest in FSGS (.6 years IQR .2‐2.9) and longest in MN (6.3 years IQR 3.3‐8.0) whereas time to graft loss after diagnosis was shortest in MPGN (.3 years IQR .1‐1.7) and longest in IgAN (2.9 year IQR 1.3‐4.3). Recipients with recurrent IgAN were likely to be younger, have higher proteinuria at diagnosis, receive living donor allografts, receive cyclosporine treatment, have a history of acute rejection, and have segmental sclerosis in native glomeruli. Younger age of the donors, higher proteinuria at diagnosis, alemtuzumab, proteinuria within the first 12 months, acute rejection, low baseline eGFR, mesangial proliferation, and IgG and IgA deposits were associated with FSGS recurrence. MPGN recurrence was predicted by lower BMI at transplantation, and crescentic native disease. Death‐censored graft survival at 5‐, 10‐, and 15‐years was 83%, 51%, and 29% in the RGN group and 95%, 93%, and 84%, respectively in the non‐RGN group. Over 15 years, recipients with RGN are nine times more likely than those without RGN to lose their grafts, regardless of donor type, acute rejection, and baseline eGFR. Transplant recipients of related donor allograft were not more likely to have recurrent GN than non‐related donors.

Publisher

Wiley

Subject

Transplantation

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3